{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268165","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.294899+00:00","generated_at":"2026-06-09T03:21:04.930504+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Neumora Q3 net loss $53.0M; cash $519.5M; navacaprant Phase 3 on track","bullets":["Net loss of $53.0M in Q3 2023 vs. $29.3M in Q3 2022, driven by higher R&D costs ($41.6M vs. $22.5M).","Cash, cash equivalents and marketable securities of $519.5M as of Sept 30, 2023; expected to fund operations into 2026.","Navacaprant (KOR antagonist) Phase 3 KOASTAL trials ongoing; KOASTAL-1 topline data expected H2 2024; bipolar depression trial planned H1 2024.","Completed IPO in Sept 2023; shares began trading on Nasdaq under NMRA; raised over $850M since inception.","Appointed Robert Lenz, M.D., Ph.D., as EVP, head of R&D in October 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268165","json":"https://secwatch.observer/filing/0001193125-23-268165.json","markdown":"https://secwatch.observer/filing/0001193125-23-268165.md","text":"https://secwatch.observer/filing/0001193125-23-268165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312523268165/0001193125-23-268165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312523268165/d518702d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T03:21:04.930504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5d1071a3a3f15526cd8da9c95896adacb9e1117","claim":"Neumora Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $53.0 million.","evidence_excerpt":"The Company reported a net loss of $53.0 million for the third quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312523268165/0001193125-23-268165-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$53.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}